Evidence map›Paper›PMID 41907443›Full record

ReviewiScience2026

Plant natural products targeting NLRP3 inflammasome in Parkinson's disease: Molecular activation and regulation to therapeutics.

Hao Lu, Fengyi Zeng, Jiao Sun, Baiyang Li, Zhimei Lei, Chenyu Zeng, Chendan Zhu, Yanmei Sheng, Quekun Peng, Yiran Sun and 1 more

Abstract readReview
In one paragraph

Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hao LuSchool of Biosciences and Technology, Sichuan Higher Education Institute Key Laboratory of Major Disease Target Discovery and Protein Drug Development, Chengdu Medical College, Chengdu 610500, Sichuan Province, China.
Fengyi ZengKey Laboratory of Structure-Specific Small Molecule Drugs at Chengdu Medical College of Sichuan Province, School of Pharmacy, Chengdu Medical College, Chengdu 610500, China.
Jiao SunKey Laboratory of Structure-Specific Small Molecule Drugs at Chengdu Medical College of Sichuan Province, School of Pharmacy, Chengdu Medical College, Chengdu 610500, China.
Baiyang LiThe First Affiliated Hospital of Traditional Chinese Medicine of Chengdu Medical College·Xindu Hospital of Traditional Chinese Medicine, Chengdu Medical College, Chengdu 610500, Sichuan Province, China.
Zhimei LeiKey Laboratory of Structure-Specific Small Molecule Drugs at Chengdu Medical College of Sichuan Province, School of Pharmacy, Chengdu Medical College, Chengdu 610500, China.
Chenyu ZengKey Laboratory of Structure-Specific Small Molecule Drugs at Chengdu Medical College of Sichuan Province, School of Pharmacy, Chengdu Medical College, Chengdu 610500, China.
Chendan ZhuKey Laboratory of Structure-Specific Small Molecule Drugs at Chengdu Medical College of Sichuan Province, School of Pharmacy, Chengdu Medical College, Chengdu 610500, China.
Yanmei ShengKey Laboratory of Structure-Specific Small Molecule Drugs at Chengdu Medical College of Sichuan Province, School of Pharmacy, Chengdu Medical College, Chengdu 610500, China.
Quekun PengSchool of Biosciences and Technology, Sichuan Higher Education Institute Key Laboratory of Major Disease Target Discovery and Protein Drug Development, Chengdu Medical College, Chengdu 610500, Sichuan Province, China.
Yiran SunKey Laboratory of Structure-Specific Small Molecule Drugs at Chengdu Medical College of Sichuan Province, School of Pharmacy, Chengdu Medical College, Chengdu 610500, China.
Shiyan ZhangDepartment of Scientific Research Management, Zhoukou Central Hospital, Zhoukou, Henan 466000, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons and the pathological accumulation of α-synuclein (α-syn), a key neuronal protein implicated in neuroinflammation and disease progression. The NOD-like receptor protein 3 (NLRP3) inflammasome, a critical component of the innate immune system, serves as a macromolecular sensor for damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs). Its aberrant activation drives chronic neuroinflammation, which exacerbates PD pathology. This review elucidates the molecular mechanisms underlying NLRP3 inflammasome activation and its intricate relationship with PD, emphasizing the role of α-syn as a DAMP that triggers NLRP3 via Toll-like receptors (TLRs) and mitochondrial dysfunction. The review highlights how mitochondrial impairment and lysosomal disruption amplify NLRP3 activation, creating a vicious cycle of neuroinflammation and neuronal death. Importantly, emerging evidence demonstrates that plant natural products (PNPs) can effectively target the NLRP3 inflammasome pathway, offering a promising avenue for PD therapy. This review not only establishes the NLRP3 inflammasome as a pivotal macromolecular target in PD therapy but also systematically demonstrates, from the perspectives of structural biology, immunology, and translational medicine, the significant value of PNPs as a novel class of precision neuroprotective modulators-thereby laying a theoretical foundation for developing multi-target, low-toxicity therapeutic agents against PD.

Indexed as

health sciencesmedicinenatural product chemistryneurology

Identifiers

PMID41907443
PMCPMC13019509

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.